Why your doctor may choose DOXIL®
DOXIL® is indicated for the treatment of AIDS-related Kaposi’s Sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. Treatment is continued until the cancer worsens or side effects become intolerable.
Acquired immune deficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV), which can attack and weaken the immune system and lead to infections and cancers such as AIDS-related Kaposi’s Sarcoma. Refractory or intolerant AIDS-related Kaposi’s Sarcoma is a cancer that can cause lesions in the skin, lymph nodes, and organs such as the liver, spleen, lungs, and the digestive tract. You and your doctor will discuss your treatment options and determine which treatment is right for you.
Additional information about how DOXIL® works and about refractory or intolerant AIDS-related Kaposi’s Sarcoma
Talk with your team of healthcare professionals about your refractory or intolerant AIDS-related Kaposi’s Sarcoma and what to expect from treatment.
- DOXIL® is in the anthracycline drug group, which is widely used for a variety of cancers. Anthracyclines cause cancer cells to die by damaging their DNA.
- STEALTH® technology makes DOXIL® work differently by wrapping up the chemotherapy agent doxorubicin HCl in a protective layer. This makes it harder for the immune system to find and destroy the drug, so it stays active in your body longer. Once DOXIL® reaches cancer tissue, it is slowly released. However, DOXIL® can also affect normal tissue. If you have more questions about how DOXIL® is different from other anthracyclines, ask your team of healthcare professionals.
- Kaposi’s Sarcoma is one of the most common tumors in patients with HIV/AIDS in the United States.